Abstract
Background Data on long-term outcomes of hospitalized COVID-19 patients are scarce.
Objective To provide a detailed account of hospitalized COVID-19 patients until 180 days after their initial hospitalization.
Design Nationwide cohort study using claims data from the German Local Health Care Funds, the health insurer of one-third of the German population.
Setting Germany.
Patients Adult patients hospitalized in Germany between Feb 1 and April 30, 2020 with PCR-confirmed COVID-19 and a related principal diagnosis.
Measurements Patient characteristics and ventilation status, in-hospital, 30-, 90- and 180- day mortality measured from admission, and 180-day readmission measured from discharge. Multivariable logistic regression model of independent risk factors for 180-day mortality.
Results Of 8679 patients (median age, 72 years), 2161 (24.9%) died during the index hospitalization. 30-day mortality was 23.9% (2073/8679), 90-day mortality 27.9% (2425/8679), and 180-day mortality 29.6% (2566/8679). The latter was 52.3% (1472/2817) for patients aged ≥ 80 years, and 53.0% for patients who had been ventilated invasively (853/1608). Risk factors for 180-day mortality included coagulopathy, BMI ≥ 40, and age. Female sex was a protective factor. Of 6235 patients discharged alive, 1668 patients were readmitted a total of 2551 times within 180 days, resulting in an overall readmission rate of 26.8%.
Limitations We could not stratify patients by ICU treatment as it is not coded separately. Furthermore, we cannot exclude residual confounding in our analysis of risk factors nor determine causality between risk factors and long-term mortality given the observational nature of this study.
Conclusion This nationwide cohort study of hospitalized COVID-19 patients in Germany found considerable long-term mortality and readmission rates, especially among patients with coagulopathy. Close follow-up after hospital discharge may improve long-term outcome.
Competing Interest Statement
Dr. Busse reports grants from Berlin University Alliance, during the conduct of the study; grants from Federal Ministry of Research and Education, grants from Federal Ministry of Health, grants from Innovation Fonds of the Federal Joint Committee, grants from World Health Organization, outside the submitted work, Dr. Schuppert reports grants from Bayer AG, outside the submitted work. Dr. Karagiannidis reports personal fees from Maquet, personal fees from Xenios, personal fees from Bayer, non-financial support from Speaker of the German register of ICUs, grants from German Ministry of Research and Education, during the conduct of the study. Christian Guenster, Melissa Spoden, Steffen Weber-Carstens, Gerhard Schillinger, Tanja Rombey and Dr. Hofmann have nothing to disclose.
Funding Statement
Institutional support and physical resources were provided by the University Witten/ Herdecke and Kliniken der Stadt Koeln, the Federal Association of the Local Health Care Funds and the Technical University of Berlin. The latter also received a grant from the Berlin University Alliance (112_PreEP_Corona). No funding source had a role in the design or conduct of the study; data collection, management, analysis, or interpretation; or the preparation, review, or approval of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the Witten/Herdecke University (research ethics board number 92/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail of all authors: Christian Günster (Christian.Guenster{at}wido.bv.aok.de), Reinhard Busse (rbusse{at}tu-berlin.de), Melissa Spoden (Melissa.Spoden{at}wido.bv.aok.de), Tanja Rombey (tanja.rombey{at}tu-berlin.de), Gerhard Schillinger (Gerhard.Schillinger{at}bv.aok.de), Wolfgang Hoffmann (wolfgang.hoffmann{at}uni-greifswald.de), Steffen Weber-Carstens (steffen.weber-carstens{at}charite.de), Andreas Schuppert (schuppert{at}aices.rwth-aachen.de), Christian Karagiannidis (Christian.Karagiannidis{at}uni-wh.de)
Data Availability
Data access upon personal discussion.
